BioCentury | Jun 14, 2019
Product Development

Despite senior management shake-up, Novartis’ pipeline is primed to deliver

A string of departures at Novartis AG and strategic shifts by new CEO Vasant Narasimhan have produced a fairly thorough makeover of the executive committee he inherited in 2018. The team gains a pipeline that...
BC Extra | Apr 16, 2019
Company News

Management tracks: Ginkgo Bioworks, KSQ, Milestone, Cerebral

Genetic engineering company Ginkgo Bioworks Inc. (Boston, Mass.) appointed Marijn Dekkers as chairman and strategic adviser. He was CEO of Bayer AG (Xetra:BAYN) and is currently chairman of Unilever plc (LSE:ULVR), Unilever N.V. (NYSE:UL) and...
BC Extra | Apr 9, 2019
Company News

IFM Tre deal offers glimpse into Novartis' M&A future

Novartis' acquisition of IFM Tre gives a glimpse of its M&A strategy going forward, as the pharma focuses on early stage deals and aims to keep M&A spending at 5% of market cap. Prakash Raman,...
BC Week In Review | Jul 20, 2018
Company News

Novartis halts price increases, reports 2Q earnings

Novartis AG (NYSE:NVS; SIX:NOVN) announced on July 18 that it will suspend for the rest of the year price increases in the U.S. The pharma made the announcement in conjunction with the release of its...
BC Extra | Jul 18, 2018
Company News

Novartis halts price increases, reports 2Q earnings

Novartis AG (NYSE:NVS; SIX:NOVN) announced Wednesday that it will suspend for the rest of the year price increases in the U.S. The pharma made the announcement in conjunction with the release of its 2Q18 earnings....
BC Week In Review | Jul 13, 2018
Company News

Novartis to spin out Alcon unit

Novartis AG (NYSE:NVS; SIX:NOVN) said it intends to spin out its Alcon eye care business, while retaining the pharma’s ophthalmology pharmaceuticals portfolio. The spinout will include Alcon’s surgical and vision care assets, which yielded $6.7...
BC Extra | Jun 29, 2018
Company News

Novartis to spin out Alcon unit

Novartis AG (NYSE:NVS; SIX:NOVN) said it intends to spin out its Alcon eye care business, while retaining the pharma’s ophthalmology pharmaceuticals portfolio. The spinout will include Alcon’s surgical and vision care assets, which yielded $6.7...
BC Extra | Jan 26, 2018
Politics & Policy

Narasimhan dines with Trump in Davos

Soon-to-be CEO of Novartis AG (NYSE:NVS; SIX:NOVN) Vasant Narasimhan attended a dinner with President Trump at the World Economic Forum in Davos, Switzerland on Thursday. The pharma declined to comment on what was discussed at...
BC Extra | Jan 25, 2018
Company News

Novartis gains ex-U.S. rights to Spark's gene therapy, and reports earnings

Novartis AG (NYSE:NVS; SIX:NOVN) gained ex-U.S. rights to develop and commercialize voretigene neparvovec-rzyl from Spark Therapeutics Inc. (NASDAQ:ONCE). The pharma also reported its 4Q17 earnings on Wednesday. Spark will receive $105 million up front and...
BC Week In Review | Jan 5, 2018
Financial News

Oculis raises CHF20M series B

Oculis S.A. (Lausanne, Switzerland) raised CHF20 million ($20.3 million) on Jan. 4 in a tranched series B round led by Bay City Capital, Novartis Venture Fund and Pivotal bioVenture Partners with participation by existing investors...
Items per page:
1 - 10 of 202
BioCentury | Jun 14, 2019
Product Development

Despite senior management shake-up, Novartis’ pipeline is primed to deliver

A string of departures at Novartis AG and strategic shifts by new CEO Vasant Narasimhan have produced a fairly thorough makeover of the executive committee he inherited in 2018. The team gains a pipeline that...
BC Extra | Apr 16, 2019
Company News

Management tracks: Ginkgo Bioworks, KSQ, Milestone, Cerebral

Genetic engineering company Ginkgo Bioworks Inc. (Boston, Mass.) appointed Marijn Dekkers as chairman and strategic adviser. He was CEO of Bayer AG (Xetra:BAYN) and is currently chairman of Unilever plc (LSE:ULVR), Unilever N.V. (NYSE:UL) and...
BC Extra | Apr 9, 2019
Company News

IFM Tre deal offers glimpse into Novartis' M&A future

Novartis' acquisition of IFM Tre gives a glimpse of its M&A strategy going forward, as the pharma focuses on early stage deals and aims to keep M&A spending at 5% of market cap. Prakash Raman,...
BC Week In Review | Jul 20, 2018
Company News

Novartis halts price increases, reports 2Q earnings

Novartis AG (NYSE:NVS; SIX:NOVN) announced on July 18 that it will suspend for the rest of the year price increases in the U.S. The pharma made the announcement in conjunction with the release of its...
BC Extra | Jul 18, 2018
Company News

Novartis halts price increases, reports 2Q earnings

Novartis AG (NYSE:NVS; SIX:NOVN) announced Wednesday that it will suspend for the rest of the year price increases in the U.S. The pharma made the announcement in conjunction with the release of its 2Q18 earnings....
BC Week In Review | Jul 13, 2018
Company News

Novartis to spin out Alcon unit

Novartis AG (NYSE:NVS; SIX:NOVN) said it intends to spin out its Alcon eye care business, while retaining the pharma’s ophthalmology pharmaceuticals portfolio. The spinout will include Alcon’s surgical and vision care assets, which yielded $6.7...
BC Extra | Jun 29, 2018
Company News

Novartis to spin out Alcon unit

Novartis AG (NYSE:NVS; SIX:NOVN) said it intends to spin out its Alcon eye care business, while retaining the pharma’s ophthalmology pharmaceuticals portfolio. The spinout will include Alcon’s surgical and vision care assets, which yielded $6.7...
BC Extra | Jan 26, 2018
Politics & Policy

Narasimhan dines with Trump in Davos

Soon-to-be CEO of Novartis AG (NYSE:NVS; SIX:NOVN) Vasant Narasimhan attended a dinner with President Trump at the World Economic Forum in Davos, Switzerland on Thursday. The pharma declined to comment on what was discussed at...
BC Extra | Jan 25, 2018
Company News

Novartis gains ex-U.S. rights to Spark's gene therapy, and reports earnings

Novartis AG (NYSE:NVS; SIX:NOVN) gained ex-U.S. rights to develop and commercialize voretigene neparvovec-rzyl from Spark Therapeutics Inc. (NASDAQ:ONCE). The pharma also reported its 4Q17 earnings on Wednesday. Spark will receive $105 million up front and...
BC Week In Review | Jan 5, 2018
Financial News

Oculis raises CHF20M series B

Oculis S.A. (Lausanne, Switzerland) raised CHF20 million ($20.3 million) on Jan. 4 in a tranched series B round led by Bay City Capital, Novartis Venture Fund and Pivotal bioVenture Partners with participation by existing investors...
Items per page:
1 - 10 of 202